Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.6752W HIGH $17.57
Volume
7.88 K
Value Traded
389.64 K
Short % Float
1.35%
-0.53%Week
+0.12%1 Month
+8.01%3 Month
+101.3%6 Month
-86.7%5 Year
-86.7%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
90.23 M
EPS (TTM)
8.57
P/E Ratio
1.98
Ent. Value
-2.62 M
Total Shares
5.31 M
Float Shares
4.12 M
Insiders
22.43%
Institutions
59.77%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
RLYB Catalyst Timeline
Dated clinical, regulatory and corporate events for Rallybio Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rallybio Corporation
150Total events
0Upcoming
38Tier-1 (high impact)
2021 to 2026Coverage
Event history 50
◆Trial InitiationRLYB116Trial
Initiation of Phase 2 proof of concept study in immune PTR
immune platelet transfusion refractoriness (PTR)source ↗
▲Full ResultsRLYB116Clinical Data
Positive Phase 1 results for RLYB116 demonstrating complete and sustained complement inhibition
complement-mediated diseasessource ↗
◆Topline ReadoutRLYB116Clinical Data
RLYB116 confirmatory PK PD study data expected
immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS)source ↗
▲Enrollment CompleteRLYB116Trial
Completed dosing of Cohort 1 in RLYB116 Phase 1 confirmatory PK PD study
immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS)source ↗
▲Partnership / LicenseREV102Corporate
Sale of interest in REV102 to Recursion Pharmaceuticals
hypophosphatasia (HPP)source ↗
◆Topline ReadoutRLYB116Clinical Data
Topline data from Cohort 1 of RLYB116 confirmatory PK PD study
immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS)source ↗
◆Topline ReadoutRLYB212Clinical Data
PK and safety data at time of delivery for RLYB212 sentinel participant
HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT)source ↗
▲First Patient DosedRLYB116Trial
Initiation of dosing in RLYB116 confirmatory PK PD study
immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS)source ↗
▼Trial DiscontinuedRLYB212Trial
RLYB212 Phase 2 trial discontinued due to PK results not achieving target concentrations
fetal and neonatal alloimmune thrombocytopenia (FNAIT)source ↗
▼Topline ReadoutRLYB212Clinical Data
RLYB212 Phase 2 PK results showed inability to achieve target concentrations
fetal and neonatal alloimmune thrombocytopenia (FNAIT)source ↗
▼Trial DiscontinuedRLYB212Trial
Discontinuation of RLYB212 program
fetal and neonatal alloimmune thrombocytopenia (FNAIT)source ↗
◆First Patient DosedRLYB116Trial
Initiate dosing in RLYB116 confirmatory PK PD study
complement-driven diseasessource ↗
◆Trial InitiationRLYB116Trial
RLYB116 confirmatory PK PD study to initiate dosing in Q2 2025
complement-driven diseasessource ↗
◆Topline ReadoutRLYB212Clinical Data
PK and safety data from second trimester for RLYB212 sentinel participant
HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT)source ↗
▲First Patient DosedRLYB212Trial
Sentinel participant dosed in Phase 2 trial of RLYB212
HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT)source ↗
●IND Enabling CompleteREV102Preclinical
REV102 entered IND-enabling studies in Q1 2025
hypophosphatasia (HPP)source ↗
●Poster PresentationRLYB332Presentation
Nonclinical data for RLYB332 presented at ASH 2024
Iron overload diseasessource ↗
●Poster PresentationRLYB212Presentation
Preclinical data on RLYB212 in pregnant mice presented at ASH 2024
FNAITsource ↗
●Development Candidate NominationPreclinical
ENPP1 inhibitor development candidate nomination expected in December 2024
HPPsource ↗
●Timing GuidanceRLYB116Presentation
RLYB116 update on manufacturing, biomarker data, and future plans expected in December 2024
▲Other Regulator MilestoneRLYB212Ex-US Regulatory
CTA approvals received for RLYB212 Phase 2 trial from EMA and MHRA
FNAITsource ↗
▲Biomarker DataRLYB116Clinical Data
Complement biomarker characterization completed; greater sustained free C5 reductions observed
●Enrollment UpdateTrial
Over 13,000 pregnant women screened in FNAIT natural history study as of Nov 1, 2024
FNAITsource ↗
◆Trial InitiationRLYB212Trial
Initiate RLYB212 Phase 2 dose confirmation trial in pregnant women at higher risk of FNAIT
Fetal and neonatal alloimmune thrombocytopenia (FNAIT)source ↗
◆Oral PresentationPresentation
Presentation of full data from epidemiological analysis of FNAIT risk at a scientific conference
FNAITsource ↗
◆Oral PresentationRLYB332Presentation
Presentation of nonclinical data for RLYB332
Not specified (anti-matriptase-2 antibody)source ↗
◆Development Candidate NominationPreclinical
Development candidate nomination of ENPP1 inhibitor for HPP
Hypophosphatasia (HPP)source ↗
◆Biomarker DataRLYB116Clinical Data
Full complement biomarker analysis data for RLYB116
Not specified (complement inhibitor)source ↗
▲First Patient DosedRLYB212Trial
Screening initiation expected in 4Q 2024 for RLYB212 Phase 2 trial
FNAITsource ↗
◆Poster PresentationPresentation
Presentation of data from early lead compound in nonclinical model of HPP at ASBMR meeting
Hypophosphatasia (HPP)source ↗
●Enrollment UpdateTrial
Screening in FNAIT natural history study ongoing; >12,000 pregnant women screened as of August 1, 2024
FNAITsource ↗
●Full ResultsRLYB212Clinical Data
Phase 1b proof-of-concept study results published in Thrombosis and Haemostasis
FNAITsource ↗
◆Trial InitiationRLYB212Trial
Initiate RLYB212 Phase 2 dose confirmation trial in pregnant women at higher risk of FNAIT
Fetal and neonatal alloimmune thrombocytopenia (FNAIT)source ↗
◆Oral PresentationRLYB212Presentation
Presentations and publications including additional Phase 1b data and integrated summary of clinical/nonclinical data
FNAITsource ↗
◆Manufacturing MilestoneRLYB116CMC / Inspection
Completion of RLYB116 manufacturing work
Not specified (complement inhibitor)source ↗
Past FDA Catalysts and PDUFA Decisions
How RLYB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | REV102 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C42 / 100
Pipeline Score
$72M
Pipeline Value
Fair Value
Valuation Signal
1
Drugs Scored
0.8x
rNPV / MCap
Top 34%
Micro Cap(rank 224 of 658)
Percentile Rank
Rallybio Corporation carries a moderate pipeline score (42/100), with $1.4B risk-adjusted pipeline value, led by RLYB116 in Hematologic Diseases (Phase 1), across $79B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RLYB116 Small moleculeCompletedNCT06797375 | Hematologic Diseases | Phase 1 | COMPLETED | 16 | Feb 23, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every RLYB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| RLYB116 | complement-mediated diseases | Phase 1 | 2026-02-17 | complete and sustained inhibition of terminal complement at a 300 mg doseRead More | Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal ComplementRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Uden StephenDirector, Officer (Chief Executive Officer) | Option | 22,456 115,620 held | $6.08 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RLYB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| VR Adviser, LLC | 0.1 % (-50 %) | 904.00 K | 268.53 K |
RLYB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RLYB ranks across every disease it competes in
Competitive Position is a premium feature
See how RLYB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRLYB News
RLYB▲ +16.7%on this news
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
Rallybio Corporation and Avenzo Therapeutics have announced a merger agreement aimed at advancing next-generation oncology therapies. The deal includes a substantial $215 million private placement to support their initiatives. This collaboration is expected to enhance their capabilities in developing innovative cancer treatments.
Read more →RLYB▲ +45.5%on this news
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
Rallybio Corporation has announced a merger agreement with Candid Therapeutics, aiming to create a leading company in T-cell engager therapeutics for autoimmune diseases. The merger, expected to close in mid-2026, includes a significant financing round of over $505 million. The combined entity will operate under the name Candid Therapeutics, Inc. and focus on advancing multiple clinical programs.
Read more →RLYB▼ -10.2%on this news
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
Rallybio Corporation announced positive results from its Phase 1 study of RLYB116, a C5 inhibitor targeting complement-mediated diseases. The trial showed complete and sustained inhibition of terminal complement at a 300 mg dose with a favorable safety profile. The company plans to initiate a Phase 2 study in immune platelet transfusion refractoriness in the second half of 2026.
Read more →RLYB▼ -8.1%on this news
Rallybio Announces Reverse Stock Split of Common Stock
Rallybio Corporation has announced a one-for-eight reverse stock split, approved by stockholders during a special meeting. This move is intended to enhance the company's stock price to meet Nasdaq listing requirements and provide flexibility for future business strategies. The split will take effect on February 6, 2026, and will not alter stockholders' percentage interests in the company.
Read more →RLYBRallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Rallybio Corporation has reported its financial results for the third quarter of 2025, showcasing a net income of $16 million, a turnaround from a loss the previous year. The company generated $20 million from the sale of interest in REV102 and has extended its cash runway through 2027. Progress on its lead program, RLYB116, is notable as it moves to the second cohort in its Phase 1 clinical trials, with results anticipated in Q4 2025. However, a slight decrease in revenue suggests ongoing challenges in market performance.
Read more →RLYBRallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
Rallybio Corporation has completed dosing of the first cohort in its Phase 1 confirmatory PK/PD study for RLYB116, a C5 inhibitor. Interim data shows a favorable pharmacokinetic and pharmacodynamic profile, supporting progression to the second cohort. The study aims to demonstrate sustained complement inhibition with improved tolerability. Data readouts are expected in Q4 2025.
Read more →RLYBRallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
Rallybio Corporation announced a $12.5 million equity milestone payment from Recursion, triggered by new preclinical studies for REV102, an investigational ENPP1 inhibitor for hypophosphatasia. This payment enhances Rallybio's financial stability, extending its cash runway through 2027. The company remains eligible for additional milestone payments and royalties related to the REV102 program.
Read more →RLYBRallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Rallybio Corporation announced its second quarter 2025 financial results, reporting a net loss of $9.7 million. The company is on track for data readouts from both cohorts of its RLYB116 confirmatory PK PD study in Q3 and Q4 2025, reflecting progress in its lead program. Additionally, Rallybio strengthened its financial position through the sale of its interest in REV102 for up to $25 million, extending its cash runway into mid-2027. The company continues to focus on developing therapies for rare diseases while managing its portfolio strategically.
Read more →RLYB▲ +50.2%on this news
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
Rallybio Corporation has sold its interest in the REV102 program to Recursion Pharmaceuticals for up to $25 million, including an upfront payment of $7.5 million. This transaction extends Rallybio's cash runway to mid-2027. The REV102 program is focused on treating hypophosphatasia and is currently in preclinical development. Rallybio aims to sharpen its focus on advancing its pipeline while benefiting from potential future payments related to the REV102 program.
Read more →RLYB▼ -7.3%on this news
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
Rallybio Corporation has initiated dosing in a Phase 1 confirmatory PK/PD study for RLYB116, a C5 inhibitor targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. The study will evaluate two dosing cohorts and aims to demonstrate sustained complement inhibition. Data readouts are expected in late 2025.
Read more →RLYBRallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
Rallybio Corporation has reported first quarter 2025 financial results, highlighting progress toward initiating dosing in a confirmatory pharmacokinetic pharmacodynamic study for its lead product RLYB116 in 2Q 2025. The company currently holds $54.5 million in cash, projecting operational support into the first half of 2027. Noteworthy upcoming data readouts are expected for both RLYB116 and REV102 in late 2025. However, Rallybio has faced setbacks, including the discontinuation of the RLYB212 program due to inadequate efficacy data and a significant workforce reduction.
Read more →RLYB▼ -41.2%on this news
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
Rallybio Corporation has announced the discontinuation of its RLYB212 program aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). This decision follows Phase 2 clinical trial results that revealed the drug's failure to achieve necessary pharmacokinetic target concentrations, including the minimum required for efficacy. Despite this setback, Rallybio plans to focus on the development of RLYB116 and other emerging programs, aiming to innovate within the realm of rare diseases. They intend to initiate confirmatory studies for RLYB116 in mid-2025.
Read more →RLYBRallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Rallybio Corporation reported its financial results for Q4 and the full year of 2024, showing a net loss but strong cash reserves. The company is advancing several clinical trials, including the RLYB212 Phase 2 trial, which aims to provide key safety and pharmacokinetic data in 2025. Rallybio also plans to initiate a confirmatory study for its C5 inhibitor, RLYB116, while its ENPP1 inhibitor, REV102, is moving toward a Phase 1 study in 2026. The financial results indicate improved operational discipline, yet the company still faces significant losses.
Read more →RLYBRallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates CTA Approvals Received for RLYB212 Phase 2 Clinical Trial On Track to Initiate Screening in 4Q 2024 $75.1 Million in Cash, Cash Equivale
Rallybio Corporation reported its third quarter 2024 financial results, highlighting significant developments including the approval of clinical trial applications for its RLYB212 Phase 2 trial. The company has $75.1 million in cash and equivalents, affording a financial runway into mid-2026. Progress in the RLYB116 program is promising, with important data expected to be shared in December. Despite a reported net loss of $11.5 million, the company shows improved financial management compared to the previous year.
Read more →RLYBRallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 4Q 2024 $88.6 Million in Cash
Rallybio Corporation announced its second quarter financial results for 2024, reporting a net loss of $16.2 million. The company is on track to initiate a Phase 2 trial for its lead candidate RLYB212 in pregnant women at higher risk of fetal and neonatal alloimmune thrombocytopenia by Q4 2024. Recent data suggests a significant underestimation of the number of pregnancies at risk of this condition, representing a considerable market opportunity. Rallybio also reported having $88.6 million in cash reserves, which is expected to fund operations into mid-2026.
Read more →RLYBRallybio Reports First Quarter 2024 Financial Results and Provides Business Updates On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024 $94.2 Million in Cash,
Rallybio Corporation reported its first quarter financial results for 2024, showcasing a strong cash position of $94.2 million and plans to initiate a Phase 2 trial for RLYB212 in pregnant women at risk of FNAIT. Significant developments include a collaboration with Johnson & Johnson aimed at addressing FNAIT, and the company is conducting a natural history study to better understand FNAIT risk in diverse populations. Despite a reported net loss of $19 million, Rallybio remains focused on its key clinical-stage assets.
Read more →RLYBRallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) Rallybio to Receive Funding for FNAIT Awareness Initiative and
Rallybio Corporation has announced a collaboration with Johnson Johnson to develop therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The partnership includes an equity investment of $6.6 million and aims to raise awareness about FNAIT while advancing the clinical development of Rallybio's investigational therapy, RLYB212. This therapy is designed to prevent alloimmunization in pregnant people, with a Phase 2 study expected to begin in the second half of 2024. Currently, there are no approved treatments for FNAIT, highlighting the significance of this collaborative effort.
Read more →RLYB▼ -8.7%on this news
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results -- Received Protocol Assistance Feedback from European Medicines Agency on the Phase 2 Study for RLYB212 Company to Proceed Forward with Clinical Trial
Rallybio has reported its fourth quarter and full year 2023 financial results, highlighting significant advancements in its clinical programs, particularly for RLYB212. The company received favorable feedback from the European Medicines Agency, allowing it to progress with a Phase 2 clinical trial set to begin in the second half of 2024. Despite announcing a substantial workforce cut to reinvigorate focus on its primary assets and manage operational costs, Rallybio maintains a strong financial position with $109.9 million in cash reserves projected to extend operations through mid-2026.
Read more →RLYB▲ +24%on this news· ran to +42% by day 3
Rallybio Announces Portfolio Prioritization and Provides Corporate Update Prioritization of Phase 2-ready clinical-stage programs RLYB212 for the prevention of FNAIT and RLYB116, a C5 inhibitor for the treatment of patie
Rallybio Corporation is prioritizing its portfolio of clinical-stage programs, focusing on RLYB212 and RLYB116, which aim to address serious medical needs. The company announced a significant workforce reduction of 45% to extend its cash runway into mid-2026 while streamlining operations. They plan to initiate Phase 2 trials for RLYB212 in at-risk pregnant women by the second half of 2024. Rallybio is also optimistic about advancements in the manufacturing process of RLYB116, which could enhance treatment options for patients with complement-mediated diseases.
Read more →RLYB▼ -5.5%on this news
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5 -- 100 mg Results Demonstrated a Mean Reduction of Greater than 9
Rallybio Corporation announced preliminary results from its Phase 1 study of RLYB116, an innovative subcutaneously injected inhibitor of complement component 5. The study demonstrated a significant 93% reduction in free C5 levels with a 100 mg weekly dose, indicating potential efficacy for treating generalized myasthenia gravis and other complement-mediated diseases. While the treatment showed good tolerability, there were mild adverse events, including injection site reactions. The company has extended its cash runway to support further development, focusing on manufacturing enhancements before proceeding to Phase 2 trials.
Read more →About Rallybio Corporation
Headquarters234 CHURCH STREET, NEW HAVEN, CT, 06510
BIOPHARMAWATCH ELITE PLUS
Trade the next RLYB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime